Impact of body composition on clinical outcomes in metastatic renal cell cancer

Oncologist

Volumn 16, Issue 11, 2011, Pages 1484-1486

  Tang, Patricia A ^a   Heng, Daniel Y C ^a   Choueiri, Toni K ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; PLACEBO; SORAFENIB;

ANTIANGIOGENIC THERAPY; ARTICLE; BODY COMPOSITION; BODY MASS; BODY SURFACE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; INTRAABDOMINAL FAT; KIDNEY CANCER; KIDNEY CARCINOMA; METASTASIS; MUSCLE ATROPHY; OBESITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; OBESITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 82355187953     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0337     Document Type: Article

References (26)

1. Dancey JE, Dobbin KK, Groshen S et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 2010;16:1745-1755.
2. Motzer RJ, Bacik J, Murphy BA et al. Interfer on-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-296.
3. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-2540.
4. Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with meta-static renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol 2009; 27:5794-5799.
5. Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638.
6. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010;7:245-257.
7. Chow WH, McLaughlin JK, Mandel JS et al. Obesity and risk of renal cell cancer. Cancer Epide-Miol Biomarkers Prev 1996;5:17-21.
8. Lindblad P, Wolk A, Bergström R et al. The role of obesity and weight fluctuations in the etiology of renal cell cancer: A population-based case-control study. Cancer Epidemiol Biomarkers Prev 1994;3:631-639.
9. Awakura Y, Nakamura E, Ito N et al. Influence of body mass index on prognosis of Japanese patients with renal cell carcinoma. Urology 2007;70:50-54.
10. Kamat AM, Shock RP, Naya Y et al. Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology 2004;63:46-50.
11. Hursting SD, Berger NA. Energy balance, host-related factors, and cancer progression. J Clin Oncol 2010;28:4058-4065.
12. Ceciliani F, Giordano A, Spagnolo V. The systemic reaction during inflammation: The acute-phase proteins. Protein Pept Lett 2002;9:211-223.
13. Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest 2007;117:2362-2368.
14. Leslie NR. The redox regulation of PI 3-kinase-dependent signaling. Antioxid Redox Signal 2006;8:1765-1774.
15. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8: 915-928.
16. Choueiri TK, Xie W, Kollmannsberger CK et al. The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: Results from a large international collaboration [abstract 4524]. Proc Am Soc Clin Oncol 2010;28:347s.
17. Steffens S, Grunwald V, Ringe KI et al. Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? The Oncologist 2011;16:1565-1571.
18. Health-Statistics. Key Data on Health 2002. Office for Official Luxembourg: Publications of the European Community, 2002:146.
19. 2 body surface area normalization: Problems and implications. Clin Physiol Funct Imaging 2007;27:135-137.
20. Yoshizumi T, Nakamura T, Yamane M et al. Abdominal fat: Standardized technique for measurement at CT. Radiology 1999;211:283-286.
21. Ladoire S, Bonnetain F, Gauthier M et al. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. The Oncologist 2011;16:71-81.
22. Prado CM, Lieffers JR, McCargar LJ et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol 2008;9:629-635.
23. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
24. Antoun S, Birdsell L, Sawyer MB et al. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: Results from a placebo-controlled study. J Clin Oncol 2011;28:1054-1060.
25. Bodine SC, Stitt TN, Gonzalez M et al. Akt/ mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001;3:1014-1019.
26. Antoun S, Baracos VE, Birdsell L Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010;21:1594-1598.